Plowshare Therapies LLC — SEC Form D Filing

Plowshare Therapies LLC filed an SEC Form D on August 28, 2026, reporting $6.65M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
August 28, 2026
Amount reported
$6.65M
Round stage
Pre-Seed
Industry
Biotechnology
Website
https://www.plowsharetherapies.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Children suffer from severe pediatric rare diseases, such as Maple Syrup Urine Disease (MSUD), which is a devastating metabolic disorder causing irreversible brain injury in newborns if untreated.

Solution

Plowshare Therapies is developing gene therapies to treat these conditions, starting with a gene therapy for MSUD that systemically delivers two corrected genes to restore the missing enzyme, designed as a single, lifetime treatment.

Why now

Advances in gene therapy technology and a deeper understanding of specific rare genetic disorders, combined with a commitment to serve underserved populations, enable the development of targeted, potentially curative treatments that were previously unavailable.

Verdict

Investors backed Plowshare Therapies on the promise of a single, curative gene therapy for a devastating pediatric rare disease, where existing treatments are merely palliative. This cleared because the market recognized the significant unmet medical need and the potential for a high-value therapeutic, not because the specific delivery mechanism or the full commercialization path was fully de-risked. They were implicitly betting on successful clinical translation and regulatory approval for an orphan drug, accepting the long development timeline. The limited upside stemmed from the narrow initial indication and the high cost of gene therapy development.

Source: SEC EDGAR Form D filing